Zhai Qihui Jim, Ozcan Ayhan, Hamilton Candice, Shen Steven S, Coffey Donna, Krishnan Bhuvaneswari, Truong Luan D
Departments of Pathology, The Methodist Hospital, Houston, TX 77030, USA.
Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):323-32. doi: 10.1097/PAI.0b013e3181d712ef.
PAX-2 is a transcription factor that controls the development of the kidney, organs deriving from the mesonephric (Wolffian) duct, and those related to the Müllerian duct. Although PAX-2 is shown to be a sensitive marker for tumors derived from these organs, but whether it is specific, that is, whether other tumor types also express PAX-2, has not been systematically evaluated in either primary or metastatic tumors. Tissue sections from 937 normal or reactive tissue samples, 759 primary neoplasms, and 332 metastatic neoplasms were submitted to PAX-2 immunostain. Among the non-neoplastic tissue, PAX-2 was expressed in glomerular parietal epithelial cells, renal collecting duct cells, atrophic renal tubular cells, epithelial cells of ovarian surface, fallopian tube, endocervix, endometrium, seminal vesicle, and lymphocytes. Among the primary neoplasms, PAX-2 was noted in 104/122 (85%) of renal cell carcinoma, 31/95 carcinomas of Müllerian origin, 17/17 (100%) lymphomas, 4/4 (100%) nephrogenic adenomas, and 1/16 (6%) benign parathyroid tumors, but was negative in 477 other tumors. Among the metastatic tumors, PAX-2 was noted in 70/95 (74%) metastatic renal cell carcinomas, 14/20 (70%) metastatic tumors of Müllerian origin, 1/20 (5%) metastatic colon carcinoma of lymph nodes, 1/62 (2%) metastatic breast carcinoma of lymph nodes, but was not seen in the remaining 247 metastatic tumors. PAX-2 expression in non-neoplastic mature tissue is limited to the organs whose embryonic development depends on this transcription factor. PAX-2 is a sensitive and specific marker for tumors of renal or Müllerian origin in both primary and metastatic contexts.
PAX-2是一种转录因子，可控制肾脏、源自中肾（沃尔夫管）的器官以及与苗勒管相关的器官的发育。尽管PAX-2被证明是源自这些器官的肿瘤的敏感标志物，但它是否具有特异性，即其他肿瘤类型是否也表达PAX-2，在原发性或转移性肿瘤中均未得到系统评估。对937份正常或反应性组织样本、759例原发性肿瘤和332例转移性肿瘤的组织切片进行PAX-2免疫染色。在非肿瘤组织中，PAX-2在肾小球壁层上皮细胞、肾集合管细胞、萎缩的肾小管细胞、卵巢表面上皮细胞、输卵管、宫颈内膜、子宫内膜、精囊和淋巴细胞中表达。在原发性肿瘤中，PAX-2在104/122（85%）的肾细胞癌、31/95的苗勒管起源癌、17/17（100%）的淋巴瘤、4/4（100%）的肾源性腺瘤和1/16（6%）的良性甲状旁腺肿瘤中被检测到，但在其他477种肿瘤中呈阴性。在转移性肿瘤中，PAX-2在70/95（74%）的转移性肾细胞癌、14/20（70%）的苗勒管起源转移性肿瘤、1/20（5%）的淋巴结转移性结肠癌、1/62（2%）的淋巴结转移性乳腺癌中被检测到，但在其余247例转移性肿瘤中未发现。PAX-2在非肿瘤性成熟组织中的表达仅限于其胚胎发育依赖于该转录因子的器官。PAX-2是原发性和转移性情况下肾源性或苗勒管源性肿瘤的敏感且特异的标志物。
